Logo image of VRCA

VERRICA PHARMACEUTICALS INC (VRCA) Stock Fundamental Analysis

NASDAQ:VRCA - Nasdaq - US92511W1080 - Common Stock - Currency: USD

0.7361  -0.01 (-0.78%)

After market: 0.7361 0 (0%)

Fundamental Rating

1

Overall VRCA gets a fundamental rating of 1 out of 10. We evaluated VRCA against 194 industry peers in the Pharmaceuticals industry. VRCA may be in some trouble as it scores bad on both profitability and health. VRCA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VRCA had negative earnings in the past year.
VRCA had a negative operating cash flow in the past year.
In the past 5 years VRCA always reported negative net income.
In the past 5 years VRCA always reported negative operating cash flow.
VRCA Yearly Net Income VS EBIT VS OCF VS FCFVRCA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -258.12%, VRCA is doing worse than 92.43% of the companies in the same industry.
Industry RankSector Rank
ROA -258.12%
ROE N/A
ROIC N/A
ROA(3y)-60.22%
ROA(5y)-55.89%
ROE(3y)-169.25%
ROE(5y)-136.11%
ROIC(3y)N/A
ROIC(5y)N/A
VRCA Yearly ROA, ROE, ROICVRCA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K

1.3 Margins

With an excellent Gross Margin value of 74.08%, VRCA belongs to the best of the industry, outperforming 80.54% of the companies in the same industry.
VRCA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRCA Yearly Profit, Operating, Gross MarginsVRCA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

1

2. Health

2.1 Basic Checks

VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRCA has more shares outstanding than it did 1 year ago.
VRCA has more shares outstanding than it did 5 years ago.
VRCA has a worse debt/assets ratio than last year.
VRCA Yearly Shares OutstandingVRCA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
VRCA Yearly Total Debt VS Total AssetsVRCA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

VRCA has an Altman-Z score of -18.75. This is a bad value and indicates that VRCA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -18.75, VRCA is not doing good in the industry: 84.32% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.75
ROIC/WACCN/A
WACC11.19%
VRCA Yearly LT Debt VS Equity VS FCFVRCA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M

2.3 Liquidity

VRCA has a Current Ratio of 1.34. This is a normal value and indicates that VRCA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of VRCA (1.34) is worse than 80.00% of its industry peers.
A Quick Ratio of 1.22 indicates that VRCA should not have too much problems paying its short term obligations.
VRCA has a Quick ratio of 1.22. This is in the lower half of the industry: VRCA underperforms 74.59% of its industry peers.
Industry RankSector Rank
Current Ratio 1.34
Quick Ratio 1.22
VRCA Yearly Current Assets VS Current LiabilitesVRCA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

VRCA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -71.03%.
Looking at the last year, VRCA shows a very strong growth in Revenue. The Revenue has grown by 186.92%.
EPS 1Y (TTM)-71.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.26%
Revenue 1Y (TTM)186.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-161.06%

3.2 Future

VRCA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.49% yearly.
VRCA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 91.41% yearly.
EPS Next Y-6.37%
EPS Next 2Y27.11%
EPS Next 3Y19.66%
EPS Next 5Y18.49%
Revenue Next Year108.31%
Revenue Next 2Y90.26%
Revenue Next 3Y101.87%
Revenue Next 5Y91.41%

3.3 Evolution

VRCA Yearly Revenue VS EstimatesVRCA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
VRCA Yearly EPS VS EstimatesVRCA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 1 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VRCA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRCA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRCA Price Earnings VS Forward Price EarningsVRCA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRCA Per share dataVRCA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as VRCA's earnings are expected to grow with 19.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.11%
EPS Next 3Y19.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRCA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERRICA PHARMACEUTICALS INC

NASDAQ:VRCA (2/21/2025, 8:00:01 PM)

After market: 0.7361 0 (0%)

0.7361

-0.01 (-0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners29.48%
Inst Owner Change101.48%
Ins Owners37.53%
Ins Owner Change60.83%
Market Cap66.66M
Analysts78.33
Price Target7.14 (869.98%)
Short Float %4.62%
Short Ratio4.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.16%
Min EPS beat(2)-30.9%
Max EPS beat(2)14.57%
EPS beat(4)2
Avg EPS beat(4)-5.87%
Min EPS beat(4)-30.9%
Max EPS beat(4)14.57%
EPS beat(8)4
Avg EPS beat(8)-3.84%
EPS beat(12)7
Avg EPS beat(12)12.4%
EPS beat(16)9
Avg EPS beat(16)13.93%
Revenue beat(2)1
Avg Revenue beat(2)-60.75%
Min Revenue beat(2)-137.73%
Max Revenue beat(2)16.23%
Revenue beat(4)3
Avg Revenue beat(4)6.77%
Min Revenue beat(4)-137.73%
Max Revenue beat(4)113.53%
Revenue beat(8)5
Avg Revenue beat(8)58.15%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-24.32%
PT rev (3m)-46.15%
EPS NQ rev (1m)17.97%
EPS NQ rev (3m)16.67%
EPS NY rev (1m)4.45%
EPS NY rev (3m)0.86%
Revenue NQ rev (1m)95.43%
Revenue NQ rev (3m)-53.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-26.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.83
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0.1
BVpS-0.38
TBVpS-0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -258.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.08%
FCFM N/A
ROA(3y)-60.22%
ROA(5y)-55.89%
ROE(3y)-169.25%
ROE(5y)-136.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.07%
Cap/Sales 2.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.34
Quick Ratio 1.22
Altman-Z -18.75
F-Score3
WACC11.19%
ROIC/WACCN/A
Cap/Depr(3y)166.38%
Cap/Depr(5y)1061.5%
Cap/Sales(3y)5.91%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.26%
EPS Next Y-6.37%
EPS Next 2Y27.11%
EPS Next 3Y19.66%
EPS Next 5Y18.49%
Revenue 1Y (TTM)186.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-161.06%
Revenue Next Year108.31%
Revenue Next 2Y90.26%
Revenue Next 3Y101.87%
Revenue Next 5Y91.41%
EBIT growth 1Y-53.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.45%
EBIT Next 3Y16.52%
EBIT Next 5YN/A
FCF growth 1Y-160.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-165.04%
OCF growth 3YN/A
OCF growth 5YN/A